B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

APOBEC3G

MOLECULAR TARGET

apolipoprotein B mRNA editing enzyme catalytic subunit 3G

UniProt: Q9HC16NCBI Gene: 6048912 compounds

APOBEC3G (apolipoprotein B mRNA editing enzyme catalytic subunit 3G) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting APOBEC3G

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1myricetin-3-O-galactopyranoside [Supplementary Concept]1.393
2Ampicillin Semi-synthetic derivative of penicillin that functions as1.102
3Anthralin1.102
4sulfameter1.102
5DEAD-box RNA Helicases0.691
6Thioctic Acid0.691
7Resveratrol0.691
8Cefotetan0.691
9Dimethylphenylpiperazinium Iodide0.691
10mg6240.691
11streptonigrin0.691
12Thioctic Acid0.691

About APOBEC3G as a Drug Target

APOBEC3G (apolipoprotein B mRNA editing enzyme catalytic subunit 3G) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented APOBEC3G interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

APOBEC3G inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.